-+ 0.00%
-+ 0.00%
-+ 0.00%

Japan health ministry grants orphan drug status to Vanda’s imsidolimab for pustular psoriasis

PUBT·05/27/2026 11:02:05
Listen to the news
Japan health ministry grants orphan drug status to Vanda’s imsidolimab for pustular psoriasis
  • Japan’s MHLW granted orphan drug designation to Vanda’s imsidolimab for generalized pustular psoriasis.
  • Status offers development incentives in Japan, including R&D subsidies, potential for up to 10 years of market exclusivity on approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vanda Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH68610) on May 27, 2026, and is solely responsible for the information contained therein.